Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | ALAD | P13716 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8584887 | 0.94 | CYP2A6 (0.47) | TBXAS1KDM4EGLAMEN1KMT2A | |
| SCHEMBL2082067 | 0.86 | CYP2A6 (0.53) | TBXAS1KDM4EGLAMEN1KMT2A | |
| SCHEMBL2524982 | 0.84 | DGAT1 (0.47) | KDM4EGLAMEN1KMT2ARXFP1 | |
| SCHEMBL497770 | 0.84 | CYP2A6 (0.44) | MEN1KMT2ARXFP1TSHRNPC1 | |
| SCHEMBL497960 | 0.80 | NR4A2 (0.49) | TSHRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6130739 | 0.80 | TBXAS1 (0.48) | TBXAS1MEN1KMT2ATSHRHDAC3 | |
| SCHEMBL31564131 | 0.80 | TBXAS1 (0.48) | TBXAS1KDM4ETSHRNPC1HDAC3 | |
| SCHEMBL6130768 | 0.79 | TBXAS1 (0.50) | TBXAS1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6130706 | 0.79 | BCKDK (0.49) | TBXAS1KDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL2848918 | 0.79 | MAPT (0.47) | TBXAS1KDM4EMEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984360-B1 | Compounds and methods for modulating FX-receptors | LILLY CO ELI (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7863302-B2 | Compounds and methods for modulating FX-receptors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100117066-A1 | Organic Semiconductors | MERCK PATENT GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2178851-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | Eli Lilly & Company (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-1598065-A2 | Drugs for improving prognosis of brain injury | Japan Science and Technology Agency (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-20050227984-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| US-20050222235-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | SHIONOGI & CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1535629-A1 | DRUGS FOR IMPROVING THE PROGNOSIS OF BRAIN INJURY AND A METHOD OF SCREENING THE SAME | Japan Science and Technology Agency (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20030027854-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | SHIONOGI & CO., LTD. | 2003-02-06 | — | — | US | disclosed |
| US-6506789-B2 | For prophylaxis and therapy of itching derived from contact dermatitis, allergic conjunctivitis, urticaria, atopic dermatitis | SHIONOGI & CO., LTD. (JP) | 2003-01-14 | — | — | US | disclosed |
| EP-0944614-B1 | BENZOTHIOPHENECARBOXAMIDE DERIVATIVES AND PGD2 ANTAGONISTS COMPRISING THEM | SHIONOGI & CO (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-20020058693-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | ARIMURA AKINORI (JP) | 2002-05-16 | — | — | US | disclosed |
| EP-1084711-A1 | REMEDIES FOR ITCHING CONTAINING PGD 2? ANTAGONISTS | SHIONOGI & CO., LTD. (JP) | 2001-03-21 | — | — | EP | disclosed |
| US-6083974-A | BENZOTHIOPHENECARBOXAMIDE CONTAINING NORPINANE RING IS USEFUL FOR PREVENTING NASAL BLOCKAGE | SHIONOGI & CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222235-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | HPGDS, PTGDR, PTGDR2 | TBXAS1 58/4885KDM4E 3862/4885GLA 557/4885 |
| US-20100117066-A1 | Organic Semiconductors | DBF4, DDT, SOAT1 | TBXAS1 1149/4885KDM4E 297/4885GLA 4811/4885 |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | TBXAS1 333/4885KDM4E 4157/4885GLA 2265/4885 |
| US-20020058693-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | HRH2, PTGER2, PTGDR2 | TBXAS1 195/4885KDM4E 4756/4885GLA 1593/4885 |
| US-20030027854-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | HRH2, PTGER2, PTGDR2 | TBXAS1 195/4885KDM4E 4756/4885GLA 1593/4885 |
| US-20050227984-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | HPGDS, PTGDR, PTGDR2 | TBXAS1 58/4885KDM4E 3862/4885GLA 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.